Clinically, prostate cancer is diagnosed through non-invasive screening techniques such as prostate-specific antigen (PSA) testing and digital rectal examination (DRE), with confirmation through transrectal ultrasound (TRUS) guided biopsy and histological evaluation [2]. This evidence concerns the gene KLK3 and prostate cancer.